The present invention relates to a novel Lactobacillus sp. isolation strain having an activity to inhibit the growth of vaginitis pathogens, and a pharmaceutical composition, a health functional food, and a cleansing product, comprising the strain as an active ingredient. Therefore, the present invention exhibits an effect of inhibiting the growth of Sneathia spp. pathogens associated with the infection with human papillomavirus (HPV) and the incidence of bacterial vaginitis, Gardnerella vaginalis as a vaginitis pathogen, and Candida albicans as a causative yeast of Candidal vaginitis, and an effect of recovering and maintaining the vaginal microflora, and thus can be used for the prevention and treatment of female vaginitis.

Microbial cell lines suitable for industrial-scale production of organic acids and methods of making and isolating such cell lines.

An isolated bacterial strain of Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 deposited under the DSMZ Accession No. DSM 34213 is provided; a probiotic composition including an Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 and optionally, one or more additional probiotic organisms that enhance the probiotic activity of the Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 is also provided; and a method for preventing or treating chronic kidney disease in a subject in need thereof including: administering to the subject a pharmaceutically effective amount of the probiotic composition including an isolated bacterial strain of Lactiplantibacillus plantarum subsp. plantarum MFM 30-3, and optionally, one or more additional probiotic organisms that enhance the probiotic activity of the Lactiplantibacillus plantarum subsp. plantarum MFM 30-3 is further provided.

The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection. Therefore, Lactobacillus rhamnosus CCFM1119 has great application prospects in the preparation of products (such as food or medicine) for preventing and/or treating Helicobacter pylori infection.

The disclosure discloses a strain of Lactobacillus crispatus capable of preventing and/or treating Helicobacter pylori infection, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus crispatus CCFM1118. The Lactobacillus crispatus CCFM1118 can inhibit Helicobacter pylori, specifically embodied in that: (1) the diameter of an inhibition zone of supernatant of the Lactobacillus crispatus CCFM1118 on Helicobacter pylori can reach 13.14 mm; and (2) the Lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of Helicobacter pylori to AGS cells. Therefore, the Lactobacillus crispatus CCFM1118 has great application prospects in inhibiting Helicobacter pylori (not for the purposes of disease diagnosis and treatment) and preparing Helicobacter pylori inhibitors.

Alkaline extraction followed by acid precipitation or ultrafiltration method for preparation of protein isolates from oilseeds cakes/meals is followed. The strong alkaline and acidic conditions alter the functional properties of the protein, which adversely affects its quality. The present invention provides a microbial based process to produce protein isolates/concentrates from oilseed cakes/meals or from other similar type of sources either plant or animal origin without addition of strong or diluted acid. The protein is extracted in aqueous media or alkaline aqueous media with or without containing specified salt for specified duration. The extract is centrifuged, mixed with known microbial culture (the process is not limited to the particular strain) and incubated at particular temperature and duration. The precipitated protein is recovered and dried to get protein isolates/concentrates. The process is convertible to purely chemical free process as extraction of protein in potable water, precipitation of protein using microbial culture followed by drying.

Lactobacillus fermentum is provided, where the Lactobacillus fermentum is Lactobacillus fermentum TCI757 and the Lactobacillus fermentum TCI757 was deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen under the accession number DSM 33914. A method of using Lactobacillus fermentum TCI757 of reducing fat and gaining muscle for a subject in need is also provided.

A composite bacterial agent, and an application thereof. The composite bacterial agent includes Bifidobacterium longum, Enterococcus faecalis, Enterococcus faecium, Ligilactobacillus animalis, and Companilactobacillus muruki, and provides significant effect in treating intestinal disorders and inflammatory bowel disease in felines caused by bacteria.

The present invention relates to a Lactobacillus reuteri JH53 strain with excellent organic acid resistance and conversion rate of glycerol to 1,3-propanediol, and the use thereof. The strain of the present invention has excellent organic acid resistance and conversion rate of glycerol to 1,3-propanediol compared to the parent strain. Thus, if the strain of the present invention, which is generally recognized as safe (GRAS) for humans, is used in the process of producing 1,3-propanediol from crude glycerol, it may have the advantages of being safe, being environmentally friendly, and recycling resources, unlike existing GMO strains, and thus will be very useful in related industries.

The present invention relates to microbial compositions containing Lactobacillus, and methods for reducing growth of microbes that cause infection, such as urogenital tract infection and for treating or preventing the same using the compositions thereof.